時代はカスタムメードワクチンという名の「新しい希望」へと移行するそうだが・・・

 

'New hope' in cancer cure race as personalised vaccine made from patients' own TUMOURS stops relapses after four months

• Eight head and neck cancer patients given jab after surgery to remove tumours
• None saw tumours return after four months while two relapses in control group
• Vaccine uses weakened smallpox virus and patient's own cancer cells

By Mailonline Health Team

Published: 07:09 EDT, 5 July 2022 | Updated: 07:24 EDT, 5 July 2022

A cancer jab custom-made from patients' own tumours has produced 'really hopeful' results in a trial on NHS patients.

None of the eight head and neck cancer sufferers, who had a high chance of relapse, have seen their tumours return four months after getting the vaccine.

For comparison, two in the control group who were not given the jab have already seen their cancers come back.

The vaccine, which uses similar technology to the AstraZeneca Covid jab – uses DNA taken from each patient's tumour.

The genetic snippet is then inserted into a weakened virus used to deliver the jab inside the body, training the immune system to recognise and fight the cancer if it returns.

It is given as a weekly jab for six weeks, after which patients are given a booster dose every three weeks for a year.

The new figures are too small to draw any definite conclusions, but researchers say 'all the data are pointing in the right direction'.

Technology used to make the Pfizer and Moderna Covid vaccines is also being trialled on cancer patients in the US and Europe.

Head and neck cancers are newly diagnosed in more than 12,000 people in the UK each year, and 65,000 in the US. They kill just over 4,000 Brits a year and 14,000 Americans.

There are more than 30 areas within the head and neck where cancer can develop, including the mouth and throat.

 The new vaccine - codenamed TG4050 - has been developed by the French company Transgene.

It is known as a 'viral vector vaccine', using a genetically modified vaccinia virus, the same family that causes smallpox.

The pathogen has been weakened to the point it cannot cause illness and has been used in vaccination programmes for decades.

A piece of tumour DNA is inserted into the virus so that when it is injected into the body, it can train the immune system to be on watch for these cancer cells.

The hope is that the body will be able to recognise and destroy them before they can start to multiply and form tumours.

Doctors are optimistic about the jab because it is so specific to each individual person's cancer - even though that will make it more expensive in future.

Transgene's chief medical officer Dr Maud Brandely said it provided patients with 'new hope' in the race to cure cancer.

Cancer mutations can vary between patients, but by making a custom vaccine for every patient, it should be better at targeting these mutant cells.

The vaccine is given to patients after they have had surgery to remove tumours. It is hoped the jab will catch cancer cells before they can even be found on a scan.

Brian Wright was given his 10th vaccine dose at Clatterbridge recently and has 10 more doses to go until January.

A year ago, Mr Wright had a 16-hour operation to get rid of a tumour in his mouth and swap his lower jaw with bone from his leg, followed by weeks of demanding radiotherapy.

He told Sky News: 'If you have had cancer in your throat, and they say they're going to inject you with that cancer, it just sounds…'oh no you're not'.

'But then they explained it won't give you cancer back, it will make your body immune to that cancer.'

Transgene plans to treat a total of 30 patients in the trial for head and neck cancer.

Half will be given the jab once their normal treatment ends, and the other half will get it when their cancer returns.

Consultant oncologist and director of clinical research at the Clatterbridge centre, Professor Christian Ottensmeier, told Sky News he was 'cautiously optimistic'.

'I am really hopeful, yes,' he said. 'I am quite excited about it. All the data are pointing in the right direction.'

'The immune system can see things we can't see on scans,' said Professor Ottensmeier, 'it's much smarter than human beings.'

'If we can train the immune system to pick those cells that would otherwise lead to a relapse at a time when we can't even see them, then the long-term survival chances for our patients are much higher.'

Another clinical trial of the jab on ovarian cancer patients in France and the US is also showing promising results.

https://www.dailymail.co.uk/health/article-10982859/Cancer-vaccine-new-hope-jab-patients-tumours-stopping-relapses.html

 

2022年6月16日木曜日

ヒーリング・ファクターが破壊されてしまった抗原原罪人にはもはやもうどんな薬も効かない、ｍRNA技術も無駄無駄無駄

https://tokumei10.blogspot.com/2022/06/rna.html

AIで開発されたがんワクチンで治験--NECと仏バイオ技術企業

大場みのり （編集部）

2020-01-07 12:03

 　NECとがん治療向けウイルスベース免疫治療の設計開発を行うフランスのバイオテクノロジー企業Transgene SA（Transgene）は1月7日、「TG4050」を評価する「ヒト初回投与試験」に初めて患者を登録したと発表した。TG4050とは、NECの人工知能（AI）技術とTransgeneのウイルスベクターを基にした固形がんに対する個別化免疫療法の基盤「myvacテクノロジー」を基にした治療用ワクチン。

　臨床試験の最初の段階「第I相臨床試験」では、手術後に高い再発リスクを抱える頭頸部がんの患者と、手術・アジュバント療法を行った卵巣がんの患者に投与される。アジュバント療法とは腫瘍の主な治療の後、その治療効果を高めるために抗がん剤治療などを行うことを指す。

　Transgeneのmyvacテクノロジーは、NECのAI技術であるネオアンチゲン（がん細胞の変異）予測システムで特定・選択された患者固有の変異をコードし、ウイルスベース免疫治療を短期間で始めることを可能にするという。

　TG4050は、患者固有の最大30個のネオアンチゲンを標的にするように設計されている。それらは、ネオアンチゲン予測システムを用いて選択される。予測システムは20年以上にわたるAIの専門知識に基づいており、独自の免疫データで訓練され、最も免疫原性の高い配列を効率的に優先順位付けして選択できるという。

　Transgeneは、myvacを用いたウイルスベクター技術の専門性を生かしてMVA（Modified Vaccinia Virus Ankara）ウイルスベクターのゲノムに、選択されたネオアンチゲンの配列を組み込む。またTransgeneは、この新しい治療用ワクチンの臨床開発に必要なTG4050の患者ごとのロット製造のため、社内GMP（Good Manufacturing Practice）ユニットを立ち上げたとのことだ。 

https://japan.zdnet.com/article/35147665/

、、、（爆ｗｗｗｗｗｗｗｗｗｗｗｗｗ